Technology area: Biotechnology & Pharmaceuticals
30 pending office actions • 7 clients • 28 examiners • 22 art units • 0 of 30 (0%) have an AI response strategy ready • 9 patents granted in the last 365 days
UVA-Jenkins, Taylor & Hunt has 30 pending office actions in Biotechnology & Pharmaceuticals and 243 career applications. The pending docket is shown against a recorded application base, providing context for the practice’s prosecution activity.
The resolved allowance rate is 67.95%, and the average is 4.26 office actions per allowance. Resolved matters therefore show substantial examination activity before allowance, while the allowance rate describes the reported outcome for that record.
Practitioners can use this profile to distinguish workload from historical performance. The application total frames the available activity, and the outcome measures can inform planning for repeated responses, claim development, and the effort required to pursue allowance in this technology area.
Based on the USPTO statutory response window for each pending office action. 14 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 14 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (7%) |
| §103 only | 11 (37%) |
| §102 only | 1 (3%) |
| §112 only | 3 (10%) |
| Double-patenting + other | 1 (3%) |
| Multi-statute (no §101) | 11 (37%) |
| No statute on record | 1 (3%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SCHACHERMEYER, SAMANTHA LYNN | 2 | 35.7% | +70.8% |
| SHUPE, ELIZABETH A | 2 | 65.8% | +45.5% |
| DANG, RACHEL YEN VI | 1 | 100.0% | +0.0% |
| DUFFY, BRADLEY | 1 | 54.4% | +46.0% |
| CHEONG, CHEOM-GIL | 1 | 64.1% | +53.1% |
| MOORE, SUSANNA | 1 | 68.0% | +31.6% |
| FANG, MICHAEL YIMING | 1 | 62.1% | +36.7% |
| GANGLE, BRIAN J | 1 | 76.8% | +14.6% |
| LEE, DORIS L | 1 | 58.7% | +8.8% |
| SCHULTZ, JAMES | 1 | 58.0% | +17.3% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18854483 | AUTOMATION OF THE BLOOD INPUT FUNCTION COMPUTATION PIPELINE FOR DYNAMIC FDG PET FOR HUMAN BRAIN USING MACHINE LEARNING | DANG, RACHEL YEN VI | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17637557 | DDX17 AND NLRC4 TARGETING FOR INFLAMMATORY DISEASES | GOMEZ RODRIGUEZ, JULIO WASHINGTON | 162d overdue |
| 18316981 | COMPOSITIONS AND METHODS FOR TREATING AGE-RELATED MACULAR DEGENERATION AND GEOGRAPHIC ATROPHY | HUDSON, AMY ROSE | 127d overdue |
| 17629303 | CYSTEINE BINDING COMPOSITIONS AND METHODS OF USE THEREOF | JARRELL, NOBLE E | 8d overdue |
| 18011412 | TYPE 2 CYTOKINES AS PREDICTORS OF DISEASE SEVERITY AND/OR AS THERAPEUTIC TARGETS FOR COVID-19 | KIM, YUNSOO | 1d overdue |
| 17434692 | INDUCTION OF HIGHLY EFFICACIOUS ANTI-TUMOR AND IMMUNE MODULATING ACTIVITY: CELL-FREE OFF THE SHELF THERAPEUTIC MODALITY | BUTTICE, AUDREY L | 34d |
| 18705955 | BISPECIFIC ANTIBODIES | DUFFY, BRADLEY | — |
| 18692937 | METHODS FOR TREATING NEUROINFLAMMATION | CHEONG, CHEOM-GIL | — |
| 18685194 | SULFONYL-TRIAZOLES USEFUL AS COVALENT KINASE LIGANDS | MOORE, SUSANNA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18684813 | SYSTEMS, METHODS, AND COMPUTER READABLE MEDIA FOR PARAMETRIC FDG PET QUANTIFICATION, SEGMENTATION AND CLASSIFICATION OF ABNORMALITIES | FANG, MICHAEL YIMING | 92d overdue |
| 17050231 | COMPOSITIONS AND METHODS FOR TREATING ABDOMINAL AORTIC ANEURYSM | SHUPE, ELIZABETH A | 89d overdue |
| 17775213 | CERAMIDE ANALOG SACLAC MODULATES SPHINGOLIPID LEVELS AND MCL-1 SPLICING TO INDUCE APOPTOSIS IN ACUTE MYELOID LEUKEMIA | SCHACHERMEYER, SAMANTHA LYNN | 84d overdue |
| 18566497 | MINICELLS FROM HIGHLY GENOME REDUCED ESCHERICHIA COLI: CYTOPLASMIC AND SURFACE EXPRESSION OF RECOMBINANT PROTEINS AND INCORPORATION IN THE MINICELLS | GANGLE, BRIAN J | 15d |
| 18705955 | BISPECIFIC ANTIBODIES | DUFFY, BRADLEY | — |
| 18692937 | METHODS FOR TREATING NEUROINFLAMMATION | CHEONG, CHEOM-GIL | — |
| 18685194 | SULFONYL-TRIAZOLES USEFUL AS COVALENT KINASE LIGANDS | MOORE, SUSANNA | — |
| 18271911 | ADRENERGIC MECHANISMS OF AUDIOGENIC SEIZURE-INDUCED DEATH IN MOUSE MODEL OF SCN8A ENCEPHALOPATHY | SCHULTZ, JAMES | — |
| Client (Assignee) | Pending OAs |
|---|---|
| UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 24 |
| Manley Huang | 1 |
| THE UNIVERSITY OF MANCHESTER | 1 |
| Virginia Tech | 1 |
| University of Utah | 1 |
| WAYNE STATE UNIVERSITY | 1 |
| University of Kentucky | 1 |
| Art Unit | Apps |
|---|---|
| 1643 | 3 |
| 1645 | 2 |
| 1699 | 2 |
| 1693 | 2 |
| 1615 | 2 |
| 1677 | 2 |
| 1632 | 2 |
| 2668 | 1 |
| 1624 | 1 |
| 3798 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18854483 | AUTOMATION OF THE BLOOD INPUT FUNCTION COMPUTATION PIPELINE FOR DYNAMIC FDG PET FOR HUMAN BRAIN USING MACHINE LEARNING | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | DANG, RACHEL YEN VI | 2668 | §103 | Non-Final OA | — | Pending | Oct 04, 2024 |
| 18705955 | BISPECIFIC ANTIBODIES | Manley Huang | DUFFY, BRADLEY | 1643 | §102§103§112 | Non-Final OA | — | Pending | Apr 29, 2024 |
| 18692937 | METHODS FOR TREATING NEUROINFLAMMATION | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | CHEONG, CHEOM-GIL | 1645 | §102§103§112 | Non-Final OA | — | Pending | Mar 18, 2024 |
| 18685194 | SULFONYL-TRIAZOLES USEFUL AS COVALENT KINASE LIGANDS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | MOORE, SUSANNA | 1624 | §102§112 | Final Rejection | — | Pending | Feb 20, 2024 |
| 18684813 | SYSTEMS, METHODS, AND COMPUTER READABLE MEDIA FOR PARAMETRIC FDG PET QUANTIFICATION, SEGMENTATION AND CLASSIFICATION OF ABNORMALITIES | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | FANG, MICHAEL YIMING | 3798 | §103 | Non-Final OA | 92d overdue | Pending | Feb 19, 2024 |
| 18566497 | MINICELLS FROM HIGHLY GENOME REDUCED ESCHERICHIA COLI: CYTOPLASMIC AND SURFACE EXPRESSION OF RECOMBINANT PROTEINS AND INCORPORATION IN THE MINICELLS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | GANGLE, BRIAN J | 1645 | §112 | Final Rejection | 15d | Pending | Dec 01, 2023 |
| 18277752 | THE COMBINED INFLUENCE OF VISCOELASTIC AND ADHESIVE CUES ON FIBROBLAST SPREADING AND FOCAL ADHESION FORMATION | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | LEE, DORIS L | 1699 | §102 | Non-Final OA | — | Pending | Aug 17, 2023 |
| 18271911 | ADRENERGIC MECHANISMS OF AUDIOGENIC SEIZURE-INDUCED DEATH IN MOUSE MODEL OF SCN8A ENCEPHALOPATHY | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | SCHULTZ, JAMES | 1631 | §103 | Non-Final OA | — | Pending | Jul 12, 2023 |
| 18269147 | HYALURONAN IS A DRIVER OF COVID-19 SEVERITY | The University of Manchester | SCHACHERMEYER, SAMANTHA LYNN | 1693 | §101§102§103§112 | Final Rejection | — | Pending | Jun 22, 2023 |
| 18037684 | MULTICOMPARTMENT CONDUCTIVE COLLAGEN SCAFFOLD AND RELATED METHODS OF MAKING AND USING THE SAME | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | LIPPERT, JOHN WILLIAM | 1615 | §103 | Final Rejection | 89d overdue | Pending | May 18, 2023 |
| 18316981 | COMPOSITIONS AND METHODS FOR TREATING AGE-RELATED MACULAR DEGENERATION AND GEOGRAPHIC ATROPHY | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | HUDSON, AMY ROSE | 1636 | §103§112 | Final Rejection | 127d overdue | Pending | May 12, 2023 |
| 18031969 | COMPOSITIONS AND METHODS FOR OVERCOMING DR5-INDUCED IMMUNE EVASION BY SOLID TUMORS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | SHUPE, ELIZABETH A | 1643 | §103§112 | Final Rejection | — | Pending | Apr 14, 2023 |
| 18027202 | 3D-PRINTED MODULAR MICROCHIP WITH AN INTEGRATED IMPELLER PUMP TO MODEL INTER-ORGAN COMMUNICATION | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | GIERE, REBECCA M | 1677 | §103 | Non-Final OA | 5d overdue | Pending | Mar 20, 2023 |
| 18011412 | TYPE 2 CYTOKINES AS PREDICTORS OF DISEASE SEVERITY AND/OR AS THERAPEUTIC TARGETS FOR COVID-19 | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | KIM, YUNSOO | 1641 | §102§103Other | Non-Final OA | 1d overdue | Pending | Dec 19, 2022 |
| 17924963 | COMPOSITIONS AND METHODS FOR INDUCING IMMUNE RESPONSES AGAINST CLASS I FUSION PROTEIN VIRUSES | VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. | SINGH, SATYENDRA K | 1657 | §103§112DP | Final Rejection | — | Pending | Nov 11, 2022 |
| 17910613 | METABOLITES RELEASED FROM APOPTOTIC CELLS ACT AS NOVEL TISSUE MESSENGERS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | BARSKY, JARED | 1628 | §103 | Final Rejection | 78d overdue | Pending | Sep 09, 2022 |
| 17800387 | CAR T CELLS TARGETING THE INTEGRIN ALPHAV BETA3 EXHIBIT ROBUST ANTI-TUMOR RESPONSES AGAINST GLIOMAS AND OTHER SOLID TUMOR MALIGNANCIES | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | BELYAVSKYI, MICHAIL A | 1644 | §103 | Final Rejection | — | Pending | Aug 17, 2022 |
| 17796203 | MITIGATING CONCENTRATION EFFECTS OF ANTIBODY DIGESTION FOR COMPLETE SEQUENCE COVERAGE | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | COOK, LISA V | 1642 | §103§112 | Non-Final OA | — | Pending | Jul 28, 2022 |
| 17776563 | OPTIDICER CONSTRUCT FOR AGE-RELATED MACULAR DEGENERATION | UNIVERSITY OF UTAH RESEARCH FOUNDATION | MONTANARI, DAVID A | 1632 | §112 | Final Rejection | 66d overdue | Pending | May 12, 2022 |
| 17776524 | TREATMENT OF CLOSTRIDIUM DIFFICILE INFECTIONS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | PATTERSON, SARAH COOPER | 1675 | Other | Non-Final OA | — | Pending | May 12, 2022 |
| 17775213 | CERAMIDE ANALOG SACLAC MODULATES SPHINGOLIPID LEVELS AND MCL-1 SPLICING TO INDUCE APOPTOSIS IN ACUTE MYELOID LEUKEMIA | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | SCHACHERMEYER, SAMANTHA LYNN | 1693 | §103 | Final Rejection | 84d overdue | Pending | May 06, 2022 |
| 17769907 | CERAMIDE RATIOS AS PREDICTIVE AND THERAPEUTIC BIOMARKERS FOR LEUKEMIAS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | NGUYEN, NGOC-ANH THI | 1615 | §103 | Final Rejection | 21d | Pending | Apr 18, 2022 |
| 17637557 | DDX17 AND NLRC4 TARGETING FOR INFLAMMATORY DISEASES | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | GOMEZ RODRIGUEZ, JULIO WASHINGTON | 1637 | §102§103§112 | Non-Final OA | 162d overdue | Pending | Feb 23, 2022 |
| 17629303 | CYSTEINE BINDING COMPOSITIONS AND METHODS OF USE THEREOF | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | JARRELL, NOBLE E | 1699 | §102§112 | Non-Final OA | 8d overdue | Pending | Jan 21, 2022 |
| 17434692 | INDUCTION OF HIGHLY EFFICACIOUS ANTI-TUMOR AND IMMUNE MODULATING ACTIVITY: CELL-FREE OFF THE SHELF THERAPEUTIC MODALITY | Wayne State University | BUTTICE, AUDREY L | 1647 | §103§112 | Final Rejection | 34d | Pending | Aug 27, 2021 |
| 17429745 | SELECTION AND BLOCKADE OF FERTILIZATION COMPETENT MALE AND FEMALE GAMETES | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | KIRWIN, STEFANIE JOHANNA | 1677 | §101§102§103 | Non-Final OA | — | Pending | Aug 10, 2021 |
| 17396381 | COMPOSITIONS AND METHODS FOR CONVERTING STYRENE TO BIODEGRADABLE ALTERNATIVES | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | RAMIREZ, DELIA M | 1652 | §103§112 | Non-Final OA | — | Pending | Aug 06, 2021 |
| 17283626 | ENDOGENOUS CYTOPLASMIC ALU COMPLEMENTARY DNA IN AGE-RELATED MACULAR DEGENERATION | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | MCLEOD, AFRICA MHAIRIE | 1635 | §103 | Final Rejection | — | Pending | Apr 08, 2021 |
| 17050231 | COMPOSITIONS AND METHODS FOR TREATING ABDOMINAL AORTIC ANEURYSM | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | SHUPE, ELIZABETH A | 1643 | §112 | Final Rejection | 89d overdue | Pending | Oct 23, 2020 |
| 17045459 | 3D SPATIALLY PATTERNED LYMPH NODE ON A MICROFLUIDIC DEVICE | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | JOHNSON, KARA D | 1632 | §103 | Non-Final OA | — | Pending | Oct 05, 2020 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial68.0% of resolved applications prosecuted by Uva-Jenkins, Taylor & Hunt were allowed, across 243 applications in USPTO records.
4.26 office actions per allowed application on average.
30 pending office actions as of October 2026, for 7 clients, before 28 examiners in 22 art units.
